Please login to the form below

Not currently logged in
Email:
Password:

Ruconest

This page shows the latest Ruconest news and features for those working in and with pharma, biotech and healthcare.

EMA starts rapid review of Shire’s HAE antibody

EMA starts rapid review of Shire’s HAE antibody

Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

Latest news

  • Opdivo backed for two new uses by CHMP Opdivo backed for two new uses by CHMP

    The CHMP also recommended extensions of indications for Boehringer Ingelheim's Giotrif (afatinib), Abbvie's Humira (adalimumab), Pharming's Ruconest (conestat alfa), Takeda's TachoSil (human thrombin/human fibrinogen) and

  • Valeant and Shire said to be evaluating potential Salix bids Valeant and Shire said to be evaluating potential Salix bids

    Nevertheless, in the latter half of last year Salix introduced three new products - Ruconest for hereditary angioedema, Relistor (methylnaltrexone bromide) subcutaneous injection for chronic non-cancer pain and Uceris (budesonide) rectal

  • FDA approves drug for rare swelling diseases FDA approves drug for rare swelling diseases

    Salix and Pharming’s Ruconest is made from the milk of genetically-modified rabbits. ... Ruconest is developed in partnership by Salix Pharmaceutical and Pharming and is intended as a protein replacement in people with hereditary angioedema.

  • Meeting with resistance

    Dry eyes. Japan. Conestat alfa. Ruconest (Swedish Orphan Biovitrum). Hereditary angioedema.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... 151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor) for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics